An Optional Follow-Up Study to Evaluate the Continued Efficacy of ToleroMune HDM in House Dust Mite Allergic Subjects Following Challenge With House Dust Mite Allergen in an Environmental Exposure Chamber.
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2015
At a glance
- Drugs HDM SPIRE (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Circassia
- 14 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 20 Aug 2013 New trial record